- Conditions
- Multiple Myeloma
- Interventions
- Elotuzumab, Lirilumab, Urelumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 6
- States / cities
- Little Rock, Arkansas • Baltimore, Maryland • New York, New York + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1321–1344
of 29,129
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- B1344, Placebo
- Drug · Other
- Lead sponsor
- Tasly Biopharmaceuticals Co., Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Hearing Loss, Depression
- Interventions
- Phonak Audeo B-R 90 hearing aid device (Active), Duloxetine or escitalopram, Audeo B-R 90 hearing aid device (Sham)
- Device · Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 60 Years to 99 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pneumonia, Severe Acute Respiratory Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
- Interventions
- Best Practice, Low Dose Radiation Therapy
- Other · Radiation
- Lead sponsor
- Emory University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Pancreatic Cancer Stage IVA
- Interventions
- Gemcitabine, docetaxel, and capecitabine, Radiation therapy with gemzar
- Drug · Radiation
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Neoplasms, Ovarian
- Interventions
- SB-485232 (interleukin 18), pegylated liposomal doxorubicin
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 3
- States / cities
- Stanford, California • Miami, Florida • Philadelphia, Pennsylvania
- Conditions
- Breast Cancer
- Interventions
- Doxorubicin, Cyclophosphamide, Paclitaxel, Carboplatin, GM-CSF, Trastuzumab
- Drug
- Lead sponsor
- Rita Sanghvi, Mehta
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Hepatic Impairment
- Interventions
- PF-04965842
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Saint Paul, Minnesota
- Conditions
- Multiple Myeloma
- Interventions
- Elotuzumab
- Drug
- Lead sponsor
- Sundar Jagannath
- Other
- Eligibility
- 18 Years and older
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Gastrointestinal Neoplasms, Genitourinary Cancer, Thoracic Cancer, Sarcoma, Melanoma
- Interventions
- ICI Therapy
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Multiple Myeloma
- Interventions
- Dexamethasone
- Drug
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Drug Interaction
- Interventions
- Loperamide / Red Grapefruit Juice, Loperamide/ White Grapefruit Juice, Loperamide / Pink Grapefruit Juice
- Drug
- Lead sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
- Industry
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Prostate Cancer
- Interventions
- APC-100
- Drug
- Lead sponsor
- Adamis Pharmaceuticals Corporation
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Madison, Wisconsin
- Conditions
- Hand Injuries
- Interventions
- Volar digital block with lidocaine, Volar digital block with saline, Dorsal digital block with lidocaine, Dorsal digital block with saline
- Procedure
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Metastatic Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Tumor
- Interventions
- Talazoparib, ASTX727
- Drug
- Lead sponsor
- Kathy Miller
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • Winston-Salem, North Carolina
- Conditions
- Healthy
- Interventions
- Lamotrigine
- Drug
- Lead sponsor
- Dr. Reddy's Laboratories Limited, India
- Industry
- Eligibility
- 18 Years to 41 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Type 1 Diabetes
- Interventions
- Pneumovax 23- pneumococcal polysaccharide, Blood draw
- Biological · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Primary Immunodeficiency
- Interventions
- Gamunex-C, IVIG-PEG
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • North Palm Beach, Florida • South Bend, Indiana + 6 more
- Conditions
- Diabetes Mellitus Type 1
- Interventions
- Allogeneic Pancreatic Endocrine Cell Clusters
- Biological
- Lead sponsor
- Seraxis
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
- Conditions
- COVID-19
- Interventions
- hAd5-S-Fusion+N-ETSD, Placebo (0.9% (w/v) saline)
- Biological
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Acute Myeloid Leukemia, Essential Thrombocythemia
- Interventions
- LY573636-sodium
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Aurora, Colorado • Baltimore, Maryland + 2 more
- Conditions
- Pancreatic Neoplasms
- Interventions
- Gemcitabine with escalating ascorbic acid
- Drug
- Lead sponsor
- Joseph J. Cullen
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Hematologic Malignancies
- Interventions
- Cyclophosphamide
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Locally Advanced or Metastatic Breast Cancer
- Interventions
- Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg, Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg, Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg, Ixabepilone + Lapatinib + Capecitabine
- Drug
- Lead sponsor
- R-Pharm
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey